Solubility Enhancement

Icon of a newspaper with the text "Tech Bulletin" in orange below, featuring a blue and orange design that highlights advances in API flowability for direct compression.

Lipid-Based Liquid-Filled Capsules for Poorly Soluble Drugs

For a drug substance administered via oral route, it should possess adequately aqueous solubility before passes through the gastrointestinal tract to complete the absorption, and then enters the blood steams for the pharmacological actions. Hence the solubility of a drug …

Icon of a blue poster with a large "P" above the word "Poster," set against a white background, featuring a blue and orange curved banner. The design subtly echoes the concept of enhancing flow, akin to dry particle coating methods that optimize powder flow density.

Optimizing Lipid-Based Liquid-Filled Capsules for Poorly Soluble Drugs

Lipid-based formulation is proven to be one of the effective approaches to enhance solubility of poorly soluble drugs. At J-STAR, our scientists are experienced in this solubilization method, and at the same time, applying it to liquid-filled capsules to simplify …

Icon of a blue poster with a large "P" above the word "Poster," set against a white background, featuring a blue and orange curved banner. The design subtly echoes the concept of enhancing flow, akin to dry particle coating methods that optimize powder flow density.

Enhancing Drug Solubility: Amorphous Solid Dispersion Techniques

Research studies show that the majority of API candidates in the development pipeline have a BCS Class II rating, which means those APIs need a solubilization strategy to promote the bioavailability to improve their chance of clinical success.

One commercially …

Icon of a blue folded brochure with text lines, set on a white background with blue and orange curves, symbolizing the interface between design and information. The word "BROCHURE" is in bold orange letters below.

Bridging the Drug Substance and Drug Product Interface

With the ability to develop both Drug Substance (DS) and Drug product (DP) under the same umbrella, our team enjoys a synergism absent in most CROs. The ability to bridge the DS/DP interface is a major competitive advantage, and we …